How Technology Can Address Upcoming Big Pharma Financial Crunch
In this interview, we speak with Jim Corrigan, CEO of YPrime, about the future of clinical trial technologies. The...
Advancing Leukemia Care with Sellas: GPS & SLS009 Insights
We had the opportunity to speak with Dr. Angelos M. Stergiou, MD, Sc.D. h.c., about potential advancements in leukemia...
Transforming Biologic Delivery: An Interview with Surf Bio
In this interview, we speak with Bryan Mazlish, CEO of Surf Bio, about their innovative SnapShotÔ technology. Bryan discusses...
Pain Treatment Market 2024-2029: Medtronic, Abbott, GSK, Pfizer, J&J
The global conventional and alternative pain treatment market, valued at $96.2 billion in 2024, is projected to reach $144.2...
Carmell Secures Pipe Investment for Commercial Expansion
Carmell Corporation (Nasdaq: CTCX) recently closed a private placement, raising $1.85 million by issuing 8,065,210 shares of common stock...
Taysha Gene Therapies Announces Inducement Grant
Taysha Gene Therapies granted a new employee an option to purchase 311,000 shares of company stock. The option, granted...
The Emergence of Superintelligence in Healthcare, Biotech, and Clinical Trials
The journey toward superintelligence unlocks extraordinary capabilities poised to revolutionize medicine and healthcare. These systems can process vast amounts...
Capricor Submits Deramiocel BLA to FDA for Duchenne Muscular Dystrophy
Capricor Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for deramiocel, a cell therapy designed...
Pfizer & Atavistik Bio Partner to Discover Allosteric Therapeutics
Atavistik Bio and Pfizer have partnered to discover novel allosteric therapeutics for two undisclosed targets chosen by Pfizer. Atavistik...
Neumora Therapeutics Reports Positive Navacaprant Data in MDD
Neumora Therapeutics announced Phase 3 trial results for its major depressive disorder (MDD) drug, navacaprant. The KOASTAL-1 study, the...